Market Cap N/A
Revenue (ttm) 84.51M
Net Income (ttm) -60.64M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 304
Avg Vol 18,892
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 79%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-n...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 652 4500
Address:
1111 Kane Concourse, Suite 301, Bay Harbor Islands, United States
makrodimutross
makrodimutross Oct. 24 at 4:52 PM
$FBIO $FBIOP this is excellent news for Helocyte. And P2 data is due any moment now from the 30 / 60 1:2 HIV study. 96 week follow up after complete enrolment was several weeks ago now.
0 · Reply
thesaltier1
thesaltier1 Oct. 24 at 12:57 PM
$FBIOP this is your gift today, derm released positive news, fbio is moving but fbiop is not, this is a disconnect. remember that as derm sales increase then cash flow increases and $FBIOP should directly benefit more than fbio....as this increases chances of dividend being restored
0 · Reply
Sawnchey
Sawnchey Oct. 23 at 4:48 PM
$FBIO $FBIOP A miss for Moderna in the CMV vaccine space. This puts all the more significance on the upcoming Triplex readouts. https://endpoints.news/modernas-cmv-vaccine-fails-phase-3-study-company-to-halt-most-development/?u=4562bd47-74cd-4c9f-9e0c-123b64557ebe&s=email&c=79153abc-da9759b9-4e537c38&utm_medium=email&utm_campaign=2316%20-%20Is%20neurology%20the%20hottest%20target%20for%20dealmaking%20Plus%20Mikael%20Dolstens%20new%20startup%20Basic&utm_content=2316%20-%20Is%20neurology%20the%20hottest%20target%20for%20dealmaking%20Plus%20Mikael%20Dolstens%20new%20startup%20Basic+CID_d55d83919f099059ced9c189f68f53e6&utm_source=ENDPOINTS%20emails&utm_term=Modernas%20CMV%20vaccine%20fails%20Phase%203%20study%20ending%20long-shot%20prevention%20effort
0 · Reply
thesaltier1
thesaltier1 Oct. 23 at 4:24 PM
$FBIOP every month that goes by is another accumulated dividend, but every month that goes by also makes me feel like I am making a big mistake....6 months ago I thought this was a steal at $6 a share....and here we are again
0 · Reply
Sawnchey
Sawnchey Oct. 11 at 1:06 PM
$FBIOP I would actually be quite happy to see a further dip here, I love buying below 7 dollars, it feels like very good value when compared against the cumulated undeclared dividends.
2 · Reply
makrodimutross
makrodimutross Oct. 10 at 7:00 PM
$FBIO $FBIOP This chart is fundamentally retarded, but it offers a glimpse of how massive the current arbitrage opportunity truly is with Fortress preferred stock. The market made sense of the capital structure for several months. Now? Apparently the future prospects for the company are still rosy on average, but the debt securities are questionable in relation to these future prospects. Make it make sense.
1 · Reply
Kconn52
Kconn52 Oct. 5 at 3:48 PM
$FBIOP I have been bidding my time before expressing my opinion but I am surprised that LR and MW were caught unaware on this CMC hiccup. Seems like poor oversight and weak management. Combined with the poor results on some other projects, it has seriously damaged their standing as leaders. Beyond all else, this concerns me greatly.
1 · Reply
makrodimutross
makrodimutross Oct. 4 at 8:52 PM
$FBIO $FBIOP My rough prediction for Q3 wrap now: Fortress / consolidated (in millions), ultra basic Revs: 18 COGS: 6 Dep./Am.: 1 R+D: 1.2 (Saving 6.9m from Q2 CKPT expenses) SG+A: 18.9 (Saving 19.9m from Q2 CKPT expenses) Interest Exp.: 2.5 Earnings at -11.6m Fortress looks like they will be burning approximately 10m per Q... even as they ramp EMROSI, the SG+A will also increase through DERM to a ceiling value TBD. Oaktree note has a 30 month interest only expense, From July 2024. That means in January 2027 they will need to begin payback of principal. Currently they've only drawn 35m, but can access another 15m if they're on their best behavior. There seems to be a way through this without another S-3 in the next 12 months. If my prediction is correct, FBIO will have around 65m in cash at this time, and approximately 6 quarters (1.5 years) to right the ship... and most certainly by January 2027. Wild card is the FDA curtailment, and their non-acceptance of "New NDA's" at this time.
3 · Reply
Zelltable
Zelltable Oct. 4 at 7:08 PM
$FBIO $FBIOP My cousin Zellchair may be questioning his entire investment and has been fickle with both preferred and common, but I am all in, baby!!! Even if waiting for preferred dividends to resume feels like waiting for Santa Clause, I don’t care! My cousin may be wasting time with his indecisiveness on these tickers, but my answer is plain and simple: FBIO and FBIOP ride or die!!
2 · Reply
Chaka1647
Chaka1647 Oct. 2 at 3:55 PM
If the commons stays elevated, can def see a raise to get $FBIOP paid off Interesting times
2 · Reply
Latest News on FBIOP
Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call Transcript

Mar 26, 2025, 7:39 PM EDT - 7 months ago

Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call Transcript

FBIO


Fortress Biotech, Inc. (FBIO) Q3 2022 Earnings Call Transcript

Nov 10, 2022, 10:42 PM EST - 3 years ago

Fortress Biotech, Inc. (FBIO) Q3 2022 Earnings Call Transcript

FBIO


Plenty Of Further Upside In Fortress Biotech

Mar 19, 2019, 12:01 PM EDT - 7 years ago

Plenty Of Further Upside In Fortress Biotech

FBIO


makrodimutross
makrodimutross Oct. 24 at 4:52 PM
$FBIO $FBIOP this is excellent news for Helocyte. And P2 data is due any moment now from the 30 / 60 1:2 HIV study. 96 week follow up after complete enrolment was several weeks ago now.
0 · Reply
thesaltier1
thesaltier1 Oct. 24 at 12:57 PM
$FBIOP this is your gift today, derm released positive news, fbio is moving but fbiop is not, this is a disconnect. remember that as derm sales increase then cash flow increases and $FBIOP should directly benefit more than fbio....as this increases chances of dividend being restored
0 · Reply
Sawnchey
Sawnchey Oct. 23 at 4:48 PM
$FBIO $FBIOP A miss for Moderna in the CMV vaccine space. This puts all the more significance on the upcoming Triplex readouts. https://endpoints.news/modernas-cmv-vaccine-fails-phase-3-study-company-to-halt-most-development/?u=4562bd47-74cd-4c9f-9e0c-123b64557ebe&s=email&c=79153abc-da9759b9-4e537c38&utm_medium=email&utm_campaign=2316%20-%20Is%20neurology%20the%20hottest%20target%20for%20dealmaking%20Plus%20Mikael%20Dolstens%20new%20startup%20Basic&utm_content=2316%20-%20Is%20neurology%20the%20hottest%20target%20for%20dealmaking%20Plus%20Mikael%20Dolstens%20new%20startup%20Basic+CID_d55d83919f099059ced9c189f68f53e6&utm_source=ENDPOINTS%20emails&utm_term=Modernas%20CMV%20vaccine%20fails%20Phase%203%20study%20ending%20long-shot%20prevention%20effort
0 · Reply
thesaltier1
thesaltier1 Oct. 23 at 4:24 PM
$FBIOP every month that goes by is another accumulated dividend, but every month that goes by also makes me feel like I am making a big mistake....6 months ago I thought this was a steal at $6 a share....and here we are again
0 · Reply
Sawnchey
Sawnchey Oct. 11 at 1:06 PM
$FBIOP I would actually be quite happy to see a further dip here, I love buying below 7 dollars, it feels like very good value when compared against the cumulated undeclared dividends.
2 · Reply
makrodimutross
makrodimutross Oct. 10 at 7:00 PM
$FBIO $FBIOP This chart is fundamentally retarded, but it offers a glimpse of how massive the current arbitrage opportunity truly is with Fortress preferred stock. The market made sense of the capital structure for several months. Now? Apparently the future prospects for the company are still rosy on average, but the debt securities are questionable in relation to these future prospects. Make it make sense.
1 · Reply
Kconn52
Kconn52 Oct. 5 at 3:48 PM
$FBIOP I have been bidding my time before expressing my opinion but I am surprised that LR and MW were caught unaware on this CMC hiccup. Seems like poor oversight and weak management. Combined with the poor results on some other projects, it has seriously damaged their standing as leaders. Beyond all else, this concerns me greatly.
1 · Reply
makrodimutross
makrodimutross Oct. 4 at 8:52 PM
$FBIO $FBIOP My rough prediction for Q3 wrap now: Fortress / consolidated (in millions), ultra basic Revs: 18 COGS: 6 Dep./Am.: 1 R+D: 1.2 (Saving 6.9m from Q2 CKPT expenses) SG+A: 18.9 (Saving 19.9m from Q2 CKPT expenses) Interest Exp.: 2.5 Earnings at -11.6m Fortress looks like they will be burning approximately 10m per Q... even as they ramp EMROSI, the SG+A will also increase through DERM to a ceiling value TBD. Oaktree note has a 30 month interest only expense, From July 2024. That means in January 2027 they will need to begin payback of principal. Currently they've only drawn 35m, but can access another 15m if they're on their best behavior. There seems to be a way through this without another S-3 in the next 12 months. If my prediction is correct, FBIO will have around 65m in cash at this time, and approximately 6 quarters (1.5 years) to right the ship... and most certainly by January 2027. Wild card is the FDA curtailment, and their non-acceptance of "New NDA's" at this time.
3 · Reply
Zelltable
Zelltable Oct. 4 at 7:08 PM
$FBIO $FBIOP My cousin Zellchair may be questioning his entire investment and has been fickle with both preferred and common, but I am all in, baby!!! Even if waiting for preferred dividends to resume feels like waiting for Santa Clause, I don’t care! My cousin may be wasting time with his indecisiveness on these tickers, but my answer is plain and simple: FBIO and FBIOP ride or die!!
2 · Reply
Chaka1647
Chaka1647 Oct. 2 at 3:55 PM
If the commons stays elevated, can def see a raise to get $FBIOP paid off Interesting times
2 · Reply
makrodimutross
makrodimutross Oct. 1 at 1:48 PM
$FBIO $FBIOP 42m on their 2024 baby shelf that can't be accessed without the reinstatement of dividends. FBIOP is looking very good here now.
1 · Reply
Chaka1647
Chaka1647 Oct. 1 at 12:12 PM
Oh well .... push out of PRV a year or so $FBIOP
1 · Reply
Alex1m2
Alex1m2 Oct. 1 at 12:12 PM
$FBIO $FBIOP Anyone has an idea how long it can take to fix this?
3 · Reply
KeepYourDayJob
KeepYourDayJob Sep. 30 at 8:49 PM
$FBIOP $FBIO That means no ATM/dilution
1 · Reply
makrodimutross
makrodimutross Sep. 30 at 8:38 PM
0 · Reply
makrodimutross
makrodimutross Sep. 30 at 8:36 PM
$FBIO $FBIOP $DERM Ding ding. Now who will be next in line after Highbridge?
0 · Reply
makrodimutross
makrodimutross Sep. 30 at 8:35 PM
$FBIOP $FBIO banging the table about this from several months ago.
0 · Reply
makrodimutross
makrodimutross Sep. 30 at 7:37 PM
$FBIO $FBIOP I remain astounded at LR's prowess with holding back AAV-ATP7A. Cyprium still has the secret sauce which when used alongside CUTX-101, looks almost curative for Menkes (preclinical). Once CUTX-101 receives approval, and clinical trials begin with AAV-ATP7A, it will look more and more like the Ace up Cyprium's sleeve. Sentynl and Zydus will need AAV-ATP7A eventually. The cost to acquire it will only increase with time and successful trials.
0 · Reply
basstid
basstid Sep. 30 at 3:41 PM
$FBIOP @Zellchair I don’t like biotech. My wife is in the field and even the times I heard rumors of acquisitions (I did not partake, you never know), and they happened, the share price is never predictable. If you end up throwing a newsletter or RSS feed or anything together I’d be interested. I have to dig up the old sub stack and see if it has alerts just in case you decide to stay in the game. I believe I ran thru a bunch last time when I was on a flight for work. I’m still uninterested in biotech overall, but I appreciate your writing style. If you want to obtain daily short data “The OCC” is who maintains all collateral for all short positions. Every day between 10p-10a EST they post a CSV of all tickers they hold collateral on. You can find it here if interested. Click “Stock Loan Balance by Security”, DL date in question, and then divide the number by the closing price. https://www.theocc.com/market-data/market-data-reports/volume-and-open-interest/stock-loan-volume
0 · Reply